KY1005

DRUG4 trials

Sponsors

Kymab Limited

Conditions

Dermatitis, AtopicImmune System DiseasesN/A

Phase 1

A Study of KY1005 in Healthy Volunteers

CompletedNCT03161288

Kymab LimitedImmune System Diseases

Start: 2017-05-29End: 2018-03-30Updated: 2019-08-29

A Study of Subcutaneous KY1005 in Healthy Volunteers

CompletedNCT04449939

Kymab LimitedImmune System Diseases

Start: 2020-07-07End: 2020-11-30Updated: 2021-09-30

Phase 2

A Study of KY1005 in Patients With Moderate to Severe Atopic Dermatitis

CompletedNCT03754309

Kymab LimitedDermatitis, Atopic

Start: 2018-12-13End: 2020-10-08Updated: 2023-01-27

Unknown Phase

A Single and Multiple Ascending Dose, Placebo-Controlled, Double-Blind, Phase 1 Study of KY1005 in Healthy Volunteers

Active, not recruitingNL-OMON45487

Kymab LimitedN/A

Start: 2017-05-29Target: 64Updated: 2024-02-28

Related Papers

520 - Evaluating the expression of OX40 and OX40 ligand in lesional skin versus non-lesional skin in volunteers with atopic dermatitis and in healthy control skin

British Journal of Dermatology2024-02-01

392 Safety of amlitelimab in a Phase 2a clinical trial of patients with moderate-to-severe atopic dermatitis

British Journal of Dermatology2023-06-01

345 Treatment with amlitelimab—a novel non-depleting, non-cytotoxic anti-OX40Ligand monoclonal antibody—reduces IL-22 serum levels in a phase 2a randomized, placebo-controlled trial in patients with moderate-to-severe atopic dermatitis

British Journal of Dermatology2023-01-2511 citations

353 Amlitelimab reduces serum IL-13 in a phase 2a clinical trial in atopic dermatitis without impacting T-cell expansion in a T-cell recall assay

British Journal of Dermatology2023-01-254 citations